EP1029077A2

EP1029077A2 - A specific and sensitive nulceic acid detection method

Info

Publication number: EP1029077A2
Application number: EP98955529A
Authority: EP
Inventors: Christoph Kessler; Gerd Haberhausen; Knut Bartl; Henrik Orum
Original assignee: Roche Diagnostics GmbH
Current assignee: Roche Diagnostics GmbH
Priority date: 1997-11-04
Filing date: 1998-11-03
Publication date: 2000-08-23
Also published as: AU2152199A; JP2001521765A; US7105318B2; AU741141B2; WO1999023249A3; US20030175765A1; CA2308368A1; WO1999024606A2; EP1029083A2; EP1029084A2; CA2308762A1; WO1999023250A2; CA2308368C; WO1999024606A3; AU1232099A; WO1999023249A2; WO1999023250A3; AU2152099A; CA2312779A1; JP2002505071A

Abstract

The invention relates to a method for detecting a nucleic acid comprising the production of a plurality of amplifications of a section of said nucleic acid with the assistance of two primers of which one can bond on a bonding sequence A of the nucleic acid and the other can bond on a bonding sequence C' which is complimentary to a sequence C. Sequence C does not overlap A and is situated in a 3' direction from A. The inventive method also includes bringing the amplifications in contact with a probe having a bonding sequence D which can bond on a sequence B, said sequence B being situated between sequences A and C, or the complement thereof. In addition, the invention relates to the detection of the construction of a hybrid out of the amplification and the probe, whereby the sequence situated between the bonding sequences A and C contains no nucleotides, said nucleotides not being linked to the bonding sequence D of the probe or to complement D' thereof.

Description

SPECIFIC AND SENSITIVE NUCLEIC ACID DETECTION METHOD

The invention relates to a method for the detection of nucleic acids, in which an amplification of a section of these nucleic acids is carried out and this section must meet certain conditions with regard to its base sequence, and a reagent kit containing two primers and a probe which define this section.

One of the most commonly used molecular biological techniques for the detection of nucleic acids is hybridization with sequence-specific probes for the detection of homologous nucleic acid sequences. The detection of nucleic acid sequences is important in the basic area, but of particular importance in various fields of application, e.g. B. in the fields of medical diagnostics, forensic diagnostics, food diagnostics, environmental diagnostics, crop protection and veterinary medicine.

Either oligonucleotides (short DNA or RNA) or polynucleotides (longer DNA or RNA) are used as probes. The shorter probes have the advantage of greater sequence selectivity compared to the longer probes, but because of the shorter hybridization range, the disadvantage of lower sensitivity. Improved sensitivity and sequence selectivity is achieved with PNA probes (peptide nucleic acids, e.g. WO 92/20702), since these probes have a higher binding affinity for nucleic acids (higher Tm) and are characterized by a higher base discrimination (ΔTm). In addition, probes for nucleic acid detection can carry labeling groups which are suitable either for capturing and / or for detecting hybrid complexes of the probe and the nucleic acid to be detected. For nucleic acid detection by hybridization, one or more probes are used either for hybridization in solution or on solid supports. For nucleic acid detection in solution, one speaks of homogeneous detection formats, for detection on solid supports and / or mediated by solid supports of heterogeneous detection formats. In the heterogeneous detection method (e.g. dot blot), the nucleic acid to be detected can be pre-bound on the solid support. Hybridization occurs by contacting a solution containing the probe. Conversely, the probe can be pre-bound on the solid support (e.g. reverse dot blot). The hybridization takes place by contacting the bound probe with a solution which contains the nucleic acid to be detected. Alternatively, the complex of nucleic acid and probe to be detected can only be formed in solution and the binding to the solid support can only take place afterwards. In the case of homogeneous test formats, e.g. B. probe pairs are used which carry energy-transferring groups and which are brought into direct contact via co-hybridization to the nucleic acid to be detected and thereby generate a signal. Alternatively, probes can also be used which, after binding to the nucleic acid to be detected, are converted from a quenched to an unquenched state by enzymatic 5'-nuclease activity in solution.

The detection of nucleic acids by probe hybridization alone has only limited sensitivity. Even with sensitive detection marker groups such as ³² P, digoxigenin, biotin, fluorescein, ruthenium chelates, fluorescein, rhodamine or AMCA, only sensitivity in the pg to fg range is possible. For sensitive nucleic acid detection, especially in the medical-diagnostic area, however, sensitivities in the ag area and a high detection specificity are necessary. This applies both to the detection of foreign nucleic acids e.g. B. in the form of infectious agents, as well as for the detection of the presence or absence or change in the body's own nucleic acids. High detection sensitivity and specificity is also of great importance in the other application areas mentioned. So some infectious agents such as. B. HCV, HIV and HBV can be detected in just a few copies in order to ensure successful medical intervention measures, e.g. B. by early drug treatment. For such early detection of infectious agents, the detection of nucleic acid sequences of the infectious agents is advantageous because, due to the availability of nucleic acid amplification techniques (nucleic acid amplification methods), sensitive detection is possible even in an early infection phase (latency phase). The possibility of the targeted multiplication of the agent to be detected exists only in the case of nucleic acids, but not in the case of immunological detection methods. In these methods, an increase in the infection-pathogen-specific particles to be detected is only possible via the humoral immune response via the formation of corresponding infection-pathogen-specific antibodies; however, this immune response occurs only after the latency period has elapsed and is a secondary reaction after infection by the pathogen. Therefore, the detection of nucleic acid hybridization has the advantage that, for. B. the infectious agent can be detected directly after infection and very sensitive.

However, the success of medical intervention measures also depends on the fact that the infectious agent can not only be detected early with high sensitivity, but also very specifically. For targeted treatment, a distinction between different infectious agents, such as. B. HAV, HBV, HCV, HTV, various herpes viruses, HPV, and the distinction of individual subtypes, such as. B. HIV-1 and HIV-2, of importance. However, it is also crucial that quantitative statements can be made and that no false positive or false negative results can be obtained, since such incorrect results may have serious therapeutic consequences. This presupposes correctness and high reproducibility of the results. Therefore, nucleic acid detection must not only be very sensitive, but also very specific and reproducible. The specific and sensitive nucleic acid detection must also be carried out quickly so that targeted therapy can take place immediately. Often it is also important to have several infectious agents such as B. HCV, HIV and HBV side by side, z. B. as part of blood bank screening tests. In the currently common nucleic acid detection tests, this is done by series-connected individual determinations of the infectious agents to be detected. This has the disadvantage that several determinations have to be carried out in succession, which is disadvantageous especially when screening large numbers of specimens. Within the framework of these nucleic acid determinations, it is desirable to have sensitive and specific test options available which, for. B. enable a rapid parallel determination of several infectious agents side by side in a single sample (multiplex determination).

When detecting the presence or absence of the body's own nucleic acid within certain genomic loci and / or their changes, such as. B. inherited, spontaneous or a mixture of inherited and spontaneous mutations, deletions, inversions, translocations, rearrangements or triplet expansions in the form of specific and / or polymorphic changes, the availability of specific and sensitive nucleic acid detection methods is also advantageous. However, the availability of specific and sensitive nucleic acid detection methods is of great importance not only in the medical sector but also in the other fields of application mentioned.

The previous test methods for the sensitive and specific detection of the presence or absence of nucleic acids are based on the combined implementation of nucleic acid amplification reactions (nucleic acid amplification) and nucleic acid detection reactions (detection).

The nucleic acid to be detected is used in a form that is accessible for the multiplication reactions, e.g. B. in the form of untreated or treated sample material and / or sample material concentration, for. B. by adsorption of the untreated or treated sample material to the surface of a solid support and subsequent absorption of this solid support. Such solid supports are e.g. B. solid supports with glass-containing surfaces. These solid supports do not Substantial purification and / or isolation of the nucleic acids to be detected, but only a concentration of sample material and possibly inactivation and / or elimination of inhibitors for the subsequent nucleic acid amplification and detection reactions. These solid supports also make it possible to provide several nucleic acids to be detected, e.g. B. in the context of multiplexing, in a form accessible for nucleic acid amplification and detection reactions possible.

Other sample preparation methods contain targeted method steps for nucleic acid-specific and / or sequence-specific binding of the nucleic acid to be detected, e.g. B. the use of solid supports with nucleic acid-specific binding groups and / or nucleic acid capture probes for the selective binding and release of the nucleic acid to be detected by nucleic acid-specific binding and subsequent dissociation between the binding group and / or carrier-bound capture probe and nucleic acid to be detected. This type of solid support requires nucleic acid-specific binding groups and / or nucleic acid capture probes on the surface of the solid support. Therefore, for

Provision of several nucleic acids to be detected, e.g. B. in the context of multiplexing, either several solid supports necessary, which is more complex, or solid supports with one or more binding groups and / or with multiple or more capture probes. Multiple capture probes contain several binding sequences for several nucleic acids to be detected. This carrier with several

Binding groups and / or several and / or multiple capture probes are, however, more complex to produce. Likewise, the reaction conditions for the targeted binding of several nucleic acids to be detected to carriers with several binding groups and / or capture probes are more difficult to set, or the binding of several types of nucleic acid to be detected to a nucleic acid-specific binding group or to a capture probe with several complementary hybridization sequences is more difficult to set.

The multiplication and detection of the provided nucleic acids to be detected takes place in heterogeneous or homogeneous nucleic acid multiplication detection formats. The nucleic acid amplification reactions and detection reactions can either successively (heterogeneous test methods) or simultaneously (homogeneous test methods). Either target-specific nucleic acid amplification reactions, target-dependent signal nucleic acid amplification reactions or signal nucleic acid amplification reactions are used as amplification reactions. Detection systems are used to detect the increased nucleic acids either by incorporating nucleotides and / or by using labeled primers or labeled probes. The detection systems used contain either direct or indirect detection markings or coupled secondary and tertiary detection components. However, the detection of the increased nucleic acids to be detected can also be carried out by spectroscopic or physical methods.

The previous nucleic acid amplification detection methods with integrated signal nucleic acid amplification reactions have the disadvantages of low sensitivity because of the non-exponential signal amplification, increased susceptibility to interference due to a stronger tendency towards background signal formation due to the large number of probe components and the formation of non-specific detection signals, since not the one to be detected

Nucleic acid itself, but only a detection signal coupled to it is amplified independently of the target. Examples are coupled signal cascades (e.g. SELF cycle) or signaling probe tree or brush structures (e.g. branched DNA).

The previous nucleic acid amplification detection methods with integrated target-dependent signal nucleic acid amplification reactions are more sensitive than the pure signal nucleic acid amplification methods because of the exponential signal amplification, but in turn have the disadvantage of the formation of non-specific detection signals, since not the nucleic acid to be detected itself, but only one derived from this in an initial target-dependent primary reaction

Detection signal in the form of a nucleic acid reporter molecule target sequence - is enzymatically propagated independently. Examples are the Qß replication reaction, in which a Qß reporter molecule is enzymatically propagated, or the ligase chain reaction, in which parts of the nucleic acid reporter molecules are linked enzymatically independently of the sequence. As nucleic acid amplification products of the most sensitive and specific exponential target-specific nucleic acid amplification reactions such as PCR (US-A-4,683,202 or EP-B-0 202 362), RT-PCR, SDA, NASBA (EP-A-0 329) 822) or TAM (WO 91/01384), were previously single- or double-stranded nucleic acid amplification products by target sequence-dependent thermocyclic or isothermal enzymatic elongation opposing primers, which are sequence-specific for the nucleic acid to be detected and at the ends of the nucleic acid amplification unit (amplicon) bind deoxyribo or ribo nucleic acids to be detected or their complements and thus limit the nucleic acid amplification products generated. With these elongation reactions, all 4 base specifics are incorporated

The nucleic acid amplification detection methods mentioned with integrated target-specific nucleic acid amplification reactions are most specific due to target sequence-dependent enzymatic nucleic acid amplification cycles. While linear target-specific nucleic acid amplification reactions, such as the cycling probe reaction, only lead to limited sensitivity, result in exponential target-specific ones Nucleic acid amplification reactions such as elongation-based reactions such as the polymerase chain reaction (PCR, RT-PCR, SDA) or transcription-based reactions such as Nucleic Acid Sequence Based Amplification (NASBA) or Transcription Mediated Amplification (TMA) have so far been the most sensitive and most specific signals

Mixed forms between target-dependent signal nucleic acid amplification and target-specific nucleic acid amplification, such as the gap-filling ligase chain reaction (gap-filling LCR, WO 90/01069), have a target-dependent reaction step compared to the unmodified LCR, this is but limited to limited sequence sections consisting of only 1 or 2 base specifics and thus more limited target specificity Various methods are available for the detection of the nucleic acid formed. The detection of the nucleic acid amplification products formed by fragment or sequence gel analysis is time-consuming and not quantitative. The detection of carrier-bound dot, slot or reverse dot blot methods is also time-consuming and not quantitative.

Quantitative sensitive and specific determinations of the nucleic acids to be detected have so far been possible in the context of heterogeneous or homogeneous target-specific exponential nucleic acid amplification reaction formats in which the nucleic acid amplification product either by built-in labels or by hybridization with a probe specific for the nucleic acid to be detected or its complement in a part of the sequence section created by elongation is intercepted. Exponential nucleic acid amplification reaction formats in which nucleic acid-binding dyes are intercalated are also sensitive, but are not sequence-specific.

In the heterogeneous reaction formats, the nucleic acid amplification product z. B. either via a primer capture modification or by an immobilized capture probe, which is complementary to an internal sequence section of the nucleic acid amplification product, bound to a solid support and incorporation of a detection-labeled nucleotide, by hybridization with a detection-labeled probe, which is complementary to an internal Sequence section of the nucleic acid

Propagation product is detected, or via a primer detection modification. In homogeneous reaction formats, detection has so far been carried out e.g. B. via the hybridization of a probe which is complementary to an internal sequence section of the nucleic acid amplification product and which bears a quenched fluorescence label, the target sequence-dependent enzymatic cancellation of the quenching being carried out by the primer elongation-related release of the quenched fluorescence-labeled nucleotide (WO 92 / 0263.8), or via the attachment and / or intercalation of a detectable molecule or a detectable group. In all previous quantitative sensitive and specific heterogeneous and homogeneous target-specific exponential nucleic acid amplification reaction formats, nucleic acid amplification units (amplicons) have so far been used which, in addition to the specific primer and probe binding sequences, additional sequences of variable length between the flanking primer binding sequences and the internal one Contained probe binding sequence. This five-part amplicon structure resulted in amplicon lengths greater than the sum of the sequence lengths of the two flanking primers and the internal probe between preferably 100 and 1000 bases (pairs). So far, optimizations of the nucleic acid amplification reaction by means of improved enzyme mixtures have mainly been directed towards longer nucleic acid amplification products.

Shorter amplicon lengths have so far only been used to detect special sequences such as e.g. B. in triplet expansions, for in-situ studies or the detection of highly fragmented nucleic acids in the context of antiquity research. However, these short amplicon lengths were detected in more time-consuming gel formats or in-situ formats, which are characterized by a lack of sensitivity and / or a lack of quantification. Other special short sequences such as short tandem repeats, short interspersed repetitive elements microsatellite sequences or HLA-specific sequences have so far only been used as primer or probe binding sequences, or in combination with other sequences.

The five-part nucleic acid amplification products have the disadvantage that they contain, in addition to the specific primer and probe binding sequences, additional sequences which extend the amplicon and reduce the overall specificity with regard to the specificity-generating primer and probe binding reactions.

The longer five-part nucleic acid amplification products used to date also have the disadvantage of longer primer elongation times and thus longer overall test times. The sensitivity is also limited by the plateau effects of the enzymes and substrates involved, which are achieved earlier with longer amplicons. Another The disadvantage of longer nucleic acid amplification products is an increasing competition between amplicon counter strand and detector or capture probe and thus reduced sensitivity. Another disadvantage is the increased possibility of non-specific binding due to the additional sequences with the consequence of an increased background and therefore lower sensitivity (lower signal-to-noise ratio). Another disadvantage of binding the nucleic acid amplification product to carrier-bound capture probes is the steric and kinetic hindrance of longer nucleic acid molecules; therefore nucleic acid amplification products of previous lengths are preferably fragmented before binding by the capture probe. Another disadvantage is the increased susceptibility to fragmentation within the amplicon sequence and thereby destruction of the nucleic acid amplification unit; this leads to lower reproducibility. Another disadvantage is that longer nucleic acid amplification products at low test temperatures of e.g. B. 37 ° C, which are specified in conventional nucleic acid analyzers, hybridize less specifically, since there is a greater difference to the melting temperature. Another disadvantage of five-part nucleic acid amplification products in the detection of several different nucleic acid amplification products is that different nucleic acid amplification lengths are formed, which make multiplex detection more difficult.

The aim of the present invention was to provide an alternative detection method for

To provide nucleic acids, which has advantages over the previously described methods.

A special object of the invention was to provide a target-dependent exponential nucleic acid amplification method for highly sensitive, highly specific, reproducible and quantifiable detection of one or more single-stranded or double-stranded nucleic acids, which in particular avoids one or more of the disadvantages mentioned.

A further object of the invention was to make the selection of the primer and probe sequences so flexible while maintaining the overall specificity that a determination several different nucleic acids to be detected in a unified reaction format using preferably partially identical primer or probe sequences is possible.

The invention relates to a method for producing a large number of amplificates of a section of this nucleic acid with the aid of two primers, one of which can bind to a first binding sequence (A) of a strand of the nucleic acid and of which the other to a second binding sequence (C), which is essentially complementary to a sequence C of this strand which does not overlap with A and is located in the 3'-direction of A, contacting the amplificates with a probe with a binding sequence D which is linked to the third one located between sequences A and C. Sequence (B) or the complement (B ') thereof, and detection of the formation of a hybrid of an amplificate and the probe, characterized in that the third sequence (B) or the complement (B ') of which does not contain any nucleotides which do not belong to the sequence region E formed from the binding sequence D of the probe and the sequence of the amplificate bound to it belong.

The invention also relates to a reagent kit for carrying out this method.

1 shows schematically the designation used in the present description for the regions on the nucleic acid to be detected.

2 shows the corresponding designation for the intermediate extension products of the primers and the amplicons (amplicons). It is also shown that the amplificates can have one or more further regions Y which lie outside the region which contains the sequence information derived from the nucleic acid to be detected.

FIG. 3 shows schematically how the binding sequences of the primer and probe are arranged in the case of the present invention. There are different alternatives I to VI, depending on whether and how the binding sequences overlap. It is only one strand of the amplificate is shown in each case. The same arrangement (only complementary) can be created for a second strand of the amplificate. A similar picture emerges for the intermediate extension products. As cases V and VI, the case is shown that, in addition to the binding sequence D, the probe also contains further regions X which do not form base pairs with the amplificate and which may be the same or different. For comparison, the prior art case is shown as VII; the sequences Z represent the additional sequences of the five-part amplicons.

4 shows sequences of the areas used, namely A ', B and C.

The synthesis of 5 '-5 "-linked primers is shown schematically in FIG. 5.

FIG. 6 shows the connections used in FIG. 5.

FIG. 7 shows a region of the HCV genome which is particularly suitable for carrying out the method according to the invention, and a sequence from which the primer and probe sequences are preferably selected. This second sequence is taken from the non-human pathogenic virus HGBV-B. The primer and probe sequences selected from this are therefore sequences which are not specific for HCV (J. Med. Virol. 48: 60-67).

Preferred sequences for primers and probes for HCV detection are shown in FIGS. 8 to 10.

Nucleic acids that can be detected with the method according to the invention can be of any origin, for example nucleic acids of viroid, viral, bacterial or cellular origin or from yeasts or fungi. Samples (specimen) in which the nucleic acid sequences to be detected or their complement are contained are e.g. B. human, animal, bacterial or vegetable liquids, or liquids from yeast or fungi, excrement, smears, cell suspensions, cultures or tissue, cell or liquid punctures. The nucleic acids are preferably in solution. So that the method according to the invention can fully develop its advantages, it has proven to be useful if the nucleic acid to be detected has a size of at least 40 bp. The nucleic acid can also be a nucleic acid produced by cloning, amplification, in vitro and in vivo amplification.

The nucleic acid to be detected can be single-stranded (in particular in the case of RNA) or double-stranded (in particular in the case of DNA). In the case of double-stranded

Nucleic acids can be propagated both strands or just one. Single or double-stranded amplificates can be formed from both types of nucleic acids, one or both of which can be used for further detection. The sequence of the probe or probes is selected accordingly.

The sample or a control sample can be positive or negative

Control nucleic acids or quantification standards can be added, which are treated similarly or identically to the nucleic acids to be detected. For example, internal or external heterologous or homologous DNA or RNA standards containing primer binding sequences homologous and probe binding sequences heterologous to the sequences of the nucleic acids to be detected can be used as standards. Conversely, it is also possible to use primer binding sequences which are heterologous, particularly in the 3 'priming region, and homologous probe binding sequences. Analog specimens which do not contain the nucleic acids to be detected or their complement are preferably used as negative controls.

Before the multiplication, the sample is preferably subjected to one or more pretreatment steps in order to bring the nucleic acids to be detected into a form capable of replication. In a first optional step, a pretreatment of the sample (specimen) takes place, by means of which the sample is brought into a form from which the nucleic acid to be detected is brought into a form suitable for the transfer of the pretreated sample into a form suitable for multiplication (for example separation interfering components from the sample).

The type of pretreatment of the sample depends on the type of sample and the complexity of the biological material in the sample. With human body fluids such as B. In a preferred embodiment, human blood is first separated of blood cells to produce plasma, serum or blood cell concentrates. By means of this separation step, the complexity of the biological sample material in the resulting fractions is significantly reduced by the sample pretreatment without the nucleic acid to be detected being substantially isolated. In the case of sputum or smears, sample pretreatment is carried out, e.g. B. by suspending the sputum or the smear in a liquid, in the case of urine z. B. by centrifugation and further processing of the fractions obtained. In the case of tissue punctures, sample pretreatment is carried out e.g. B. by suspension and treatment with a cell-aggregating agent. In the case of cerebrosidal fluid, sample pretreatment is carried out e.g. B. by centrifugation and further processing of the fractions obtained. In these cases, too, the sample pretreatment reduces the complexity of the biological sample material.

This can be followed by a step in which the nucleic acid to be detected is converted from the pretreated sample into a form which is accessible for the multiplication. Known methods are preferably used. In a preferred embodiment, the pretreated sample is lysed in a first reaction step to release the nucleic acid to be detected, eg. B. by proteinase K treatment at elevated temperatures or in deoxyribonucleic acids by alkali. In a second step, the sample pretreated by lysis is added after the addition of chaotropic agents, such as. As guanidinium hydrochloride or urea, in the presence or absence of soluble alcohols, such as. B. isopropanol, concentrated on the surface of a solid support and subsequent absorption of this solid support. Such solid supports are e.g. B. solid supports with glass-containing surfaces (e.g. magnetic particles, glass fleece with glass-containing surfaces, particles, microtiter plates, reaction vessels, dip sticks or miniaturized reaction chambers, which in turn can also be part of integrated reaction chips). This solid support is preferably used for non-sequence-specific purification, that is to say no substantial isolation of the nucleic acids to be detected from other nucleic acids, but only a concentration of sample material (nucleic acids) and, if appropriate, inactivation and / or elimination of inhibitors for the subsequent ones Nucleic acid amplification and detection reactions. These solid supports also make it possible to provide several nucleic acids to be detected, e.g. B. in the context of multiplexing, in a form accessible for nucleic acid amplification and detection reactions possible.

In another embodiment, the transfer of the nucleic acid to be detected from the pretreated sample after nucleic acid release in a first step by z. B. Proteinase K treatment at elevated temperatures or with deoxyribonucleic acids by alkali. In a second step, the lysed pretreated sample for binding the nucleic acid to be detected is brought into contact with solid supports which have been modified with nucleic acid-specific binding groups and / or capture probes specifically for the selective binding of the nucleic acid to be detected, and then the bound nucleic acid to be detected by dissociation between Binding group and / or carrier-bound capture probe and nucleic acid to be detected again eluted. Examples of nucleic acid-specific binding groups are PNA homopyrimidine oligomers such as. B. (T) ₇ -PNA or nucleic acid-binding low-molecular substances such as. B. nucleic acid intercalators, major groove binders or minor groove binders. Examples of capture probes specific for the nucleic acid to be detected are nucleic acid oligomers or nucleic acid polymers with binding sequences for one or more nucleic acids to be detected. Further examples of capture probes specific for the nucleic acid to be detected are PNA oligomers with binding sequences for one or more nucleic acids to be detected. The binding of the nucleic acid-specific binding groups or the capture probes to the solid support can be carried out with or without the interposition of spacers either covalently or via binding pairs, such as. B. BiotimStreptavidin or NLChelat.

The nucleic acid sequences used for amplification can be linear or circular and can sequence modifications and / or other modifications, such as. B. natural or artificial nucleotide analogs or equivalents thereof or base analogs or equivalents thereof, contain or be methylated, capped, polyadenylated or modified in some other way. The ones used for propagation Nucleic acids or their complement can be of natural origin, fragmented, modified or enzymatic, e.g. B. with the enzyme uracil deglycosylase (UNG), or physically pretreated, propagated, or chemically, photochemically or enzymatically generated, for. B. by chemical oligonucleotide synthesis or in vitro replication, in vitro reverse transcription or in vitro transcription.

In the first essential method step of the method according to the invention, a section of the nucleic acid to be detected is amplified. In the following, this section is also called the amplicon. This contains the sequence region between the outer ends of the binding sequences A and C or the complement thereof of the primer (the primer binding regions), and contains the binding region E of the probe or the complement thereof. According to the present invention, the amplicon (preferably the total length of the sequences of regions A, B and C) is preferably shorter than 100 nucleotides, particularly preferably shorter than 60 nucleotides, but preferably longer than 40 nucleotides. However, this does not mean that the total length of the amplificates cannot be longer, e.g. B. if the primers additionally have nucleotides. Such propagation methods are used which permit an amplification of the nucleic acid sequence to be detected or its complement, which result in the formation of tripartite mini-nucleic acid amplification products [Mini Chain Reaction (MCR)]. In principle, all nucleic acid amplification methods known in the prior art are available for this. Target-specific nucleic acid amplification reactions are preferably used. Theoretically, exponential target-specific nucleic acid amplification reactions are particularly preferably used, in which an antiparallel replication of the nucleic acid to be detected or its complement takes place, such as, for. B. elongation-based reactions such. B. the polymerase chain reaction (PCR for

Deoxyribonucleic acids, RT-PCR for ribonucleic acids) or transcription-based reactions such as B. Nucleic Acid Sequence Based Amplification (NASBA) or Transcription Mediated Amplification (TMA). Thermocyclic exponential elongation-based nucleic acid amplification reactions such as, for. B. uses the polymerase chain reaction. The for The amplification of the nucleic acids to be detected or their complement can be in the form of single-stranded or double-stranded deoxyribonucleic acids or ribonucleic acids. The aim of the amplification reaction (amplification) is to produce a large number of amplificates of a section of the nucleic acid to be detected. An amplificate is therefore understood to mean any molecular species produced using sequence information of the nucleic acid. In particular, they are nucleic acids. The term "amplificate" includes both single-stranded and double-stranded nucleic acids. In addition to the regions (amplicon) containing the sequence information of the nucleic acid on which they are based, an amplificate can also contain further regions outside the mutually pointing ends of the primer binding sites which are not directly related to sequences of the nucleic acid to be amplified. Such sequences with a length of more than 15 nucleotides preferably do not occur on the nucleic acid to be detected or its complement and cannot hybridize with it by direct base pairing. Amplificates can therefore either be identified with the

Hybridize nucleic acid itself or with its complement. Amplificates are, for example, the products of asymmetric amplification, i.e. H. an amplification in which the two strands are formed in different amounts (e.g. by using different amounts of primers) or one of the two strands is destroyed again (e.g. by RNase).

A primer in the sense of the present invention is understood to mean a molecule which can bind to a nucleic acid T or its complement via base pairings and which can be extended, preferably enzymatically. Preferred are oligonucleotides which can be extended at their 3 'end using the nucleic acid to be detected or a complement thereof as template nucleic acid. Monovalent or multivalent or monofunctional or multifunctional agents which permit nucleic acid-dependent elongation can be used as primers. These agents can also be composed of different types of molecules, e.g. B. Chimeras from PNA and nucleotide (s) or from protein / peptide and nucleotide (s). Can preferably be used as a primer Oligomers or polymers with a binding length of between 9 and 30 nt, particularly preferably between 11 and 22 nt, are used which bind antiparallel to the nucleic acid T to be detected or its complement and which act as one of several reaction partners for an enzymatic replication of the nucleic acid to be detected or its complement Act. Oligomers are particularly preferably used as primers which, after addition of a multiplication reagent by addition of at least part of the primer to the nucleic acid to be detected or its complement, initiate a directed replication of one or both strands of the nucleic acid to be detected or its complement. An example of a particularly preferred primer is an oligonucleotide with a free 3 'hydroxyl end.

The agents used as primers can contain one or more binding sequences for one or more nucleic acids to be detected or their complement and can sequence modifications, terminal and / or internal sequence additions and / or other modifications such as. B. natural or artificial nucleotide analogs or equivalents thereof, non-functional nucleotide analogs or equivalents thereof or base analogs or equivalents thereof or be methylated, capped or polyadenylated or modified in some other way. It is necessary that they have the required binding properties for the nucleic acid to be detected or their complement and that they can be extended. Preferred nucleotide equivalents are PNA monomers or PNA oligomers (WO 92/20702) with or without positive and / or negative charges in the backbone and / or in the spacer. The agents used as primers can carry modifications which are suitable either directly or indirectly via a further pair of bonds for detection and / or binding to a solid support. Preferred primer modifications are the fluorescent dyes such. B. fluorescein, rhodamine, AMCA or derivatives thereof, a partner in one of the binding pairs biotin: (strept-) avidin, digoxigeni anti-digoxigenin, digoxigeni anti-digoxigenin coupled with equorin, fluorescein: anti-fluorescein or ruthenium or rhenium chelate or equor. A particularly preferred primer modification is biotin as a capture or detection modification. The primers can contain further sequence regions Y, in particular on its 5 'end (Fig. 2). Here, 5 '-3' links as well as 5'-5 'links and / or 5' -2 'links are possible. They can also additional structural components such. B. spacers, immobilizable groups or solubility-imparting parts of the molecule or areas which can be activated with regard to priming activity, such as, for. B. AP positions.

A probe is understood to be a molecule which can hybridize with nucleic acids due to base-base interactions. Preferred probes are therefore oligonucleotides and base-containing nucleic acid mimetics, such as peptide nucleic acids (PNA). The length of a probe, based on the binding sequence D, is preferably between 9 and 30 bases.

PNA oligomer probes with or without positive or negative charges in the backbone and or spacers have the additional advantages that they are stable against the degradation of nucleases or proteases because of the different structure of the backbone and the H or NH ₂ ends, a higher melting point in binding complexes between nucleic acids and PNA than between two

Nucleic acid molecules and the hybrid complex is therefore more stable, can be used at low salt concentrations, has a higher difference in melting points in the case of mismatches and thus better mismatch discrimination is possible, sequences with secondary structures at low salt concentrations are more accessible, the competition between amplicon Ge - Genstrang and probe is lower at low salt concentrations and thus a higher signal yield is achieved and there is the potential to eliminate the amplicon denaturation step at low salt concentrations.

Monovalent or multivalent agents can be used as probes, which allow the binding of amplification-dependent elongation products and / or increased nucleic acid sequences. Oligomers or polymers which bind antiparallel to the nucleic acid to be detected can preferably be used as probes. Oligomers are particularly preferably used as probes, which by attaching at least a part of the probe to the nucleic acid to be detected or the complement of which brings about a stable bond to one or both strands of the nucleic acid to be detected or its complement as part of the subsequent reactions. The oligomers can have 5 '-3' linkages as well as 5 '-5' linkages and / or 5 '-2' linkages as well as additional structural components such as e.g. B. spacers or solubility-imparting molecular parts.

A binding sequence is preferably understood to mean the sequence of bases which lies between the outermost bases of a particular nucleic acid, a primer or a probe, including a particular nucleic acid, a primer or a probe via base-base interaction, including these outermost bases.

The agents used as a probe may contain one or more binding sequences D for one or more nucleic acids to be detected or their complement, but in particular for one strand of the amplificate, and may include sequence modifications, terminal and / or internal sequence additions and / or other modifications such as, for. B. natural or artificial nucleotide analogs or equivalents thereof, non-functional nucleotide analogs or equivalents thereof or base analogs or equivalents thereof or be methylated, capped or polyadenylated or modified in any other way as long as binding to a strand of the amplificate is possible. Preferred nucleotide equivalents are PNA monomers or PNA oligomers with or without positive and / or negative charges in the backbone and / or spacers. The agents used as probes can carry modifications which are suitable either directly or indirectly via a further binding pair for detection and / or binding to a solid support. Preferred probe modifications (detectable groups L, immobilizable groups I) are the fluorescent dyes such as, for. B. fluorescein, rhodamine, AMCA or derivatives thereof, binding pairs biotin: (strept-) avidin, digoxigeni anti-digoxigenin, digoxigenin: anti-digoxigenin coupled with equorin, fluorescei anti-fluorescein or ruthenium chelate or equorin. Particularly preferred probe modifications are biotin as capture or detection modification, digoxigenin, ruthenium or rhenium chelate or equorin as detection modifications. In the present invention, the portion of the nucleic acid from which a large number of amplicons are to be produced is selected so that it contains three regions A, B and C. Areas A and C are areas which are selected so that one primer can use sequence A as a binding sequence and the complement of area C can serve as a binding sequence for the other primer. For the purposes of the present invention, a complement is used to form a certain other nucleic acid, e.g. B. a sequence area z. B. an amplificate or the nucleic acid to be detected is essentially complementary nucleic acid or nucleic acid sequence.

Essentially complementary means that the base pairings are selected such that (in the event that hybridization with another nucleic acid, e.g. a probe or a primer) hybridization can still take place under the test conditions or (in the case an extension product of a primer in relation to the template used) the nucleic acid could be formed due to a primer extension reaction using the corresponding nucleic acid. Essentially complementary therefore often means that under stringent conditions more than 90% of the bases of the nucleic acid or sequence under consideration form base pairings with the specific nucleic acid or sequence.

Regions A and C are preferably long enough according to the invention that conditions can be found under which primers of a corresponding length can hybridize with the bases in these regions. The regions are therefore preferably longer than 8, particularly preferably longer than 12 nucleotides. With regard to the invention, preferred ranges also result with regard to the upper limit of the length of regions A and C. The regions A and C are each preferably less than 30, particularly preferably less than 20 nucleotides. In a particular aspect of the invention, the length of the regions is limited by the fact that the primers should be able to hybridize to them in a manner that is not specific to the nucleic acid to be detected. Therefore, the particularly preferred length of the binding sequences A and C is 12 to 20 nucleotides. The areas A and C on the nucleic acid to be detected do not overlap. For the purposes of the invention, the section of the nucleic acid to be detected (which corresponds to the amplicon) and thus the amplificates formed therefrom contain a sequence B located between regions A and C (FIGS. 1 to 3). This sequence has a length of one or more nucleotides, preferably more than 4, particularly preferably more than 8 nucleotides. The length of sequence B is limited at the top by the required non-presence of nucleotides which do not belong to the binding sequence of the probe, and in a particular aspect of the invention by the desired nonspecificity of the probe. Sequence B is therefore preferably less than 30, particularly preferably less than 15 nucleotides. Sequence B preferably has a length of between 4 and 30 nucleotides. The length of the sequence B is particularly preferably between 8 and 15 nucleotides. For the purposes of the invention, this sequence or the complement thereof also serves to bind the probe. The length of the probe is chosen so that hybridization with the amplificate is possible. The sequence of the probe is selected such that it contains a binding sequence D which is defined by the nucleotides of the probe which form base-base interaction with the amplicon, in particular the nucleotides of the probe which form base interaction between the outermost bases with corresponding bases of the amplicon. The probe is preferably essentially complementary to the nucleotides of the binding sequence E of the amplificate. The binding sequence D or its complement D 'can be 100% complementary to the amplificate, but can also have mismatches (mismatches) between the outer ends of the binding sequence. In addition to the binding sequence, the probe can contain further groups or residues or also nucleic acid-binding regions (FIG. 3, V, VI).

Depending on the length of area B and the length of the binding sequence D or D ', different case configurations can be made. In a first case, the binding sequence D or D 'is longer than the region B or B' of the amplicon. In this case, the binding sequence D or D 'extends into one or both regions A or A' and C or C of the amplicon. These cases are shown in Fig. 3, II to IV. In these cases, the amplificate between the mutually pointing ends of regions A and C contains no nucleotides that are not of the binding sequence E or the binding sequences of the Belong to primer. The binding sequence D of the probe overlaps with one of the two binding sequences of the primers in FIGS. 3, II and III.

In another case, the length of area B corresponds to the length of area D, so that the binding sequence of the probe does not overlap with the binding sequences of the primers (FIGS. 3, 1).

In a preferred embodiment, the method according to the invention includes the formation of three-part mini amplicons (tripartite mini amplicon) which, in addition to the primer and probe-binding sequences, have no additional sequences and thus avoid the disadvantages in the formation of longer nucleic acid amplification products, on the other hand however, the specificity of the entire amplification format is ensured by binding the primers, by binding the probe and by running the target-dependent enzymatic elongation reaction with all 4 nucleotide or base specificities or natural or artificial analogs, isomers or equivalents thereof. The process according to the invention is therefore also referred to as a mini-chain reaction (MCR).

The nucleic acid sequences to be detected, or their complement, are amplified, unless stated otherwise, following the reaction steps and reaction conditions known to the person skilled in the art. A difference to the conventional methods is the use of specially selected primers and probe sequences, which allow the formation and multiplication of the mini tripartite amplicon. It is essential for the purposes of the invention to add one or more primers which bind to the primer binding sequences of the nucleic acid to be detected, the tripartite mini-amplicon or their complements.

It is common to add multiplying reagents that are capable of multiplying. Enzymatic active components (eg enzymes) in combination with elongation substrates and suitable auxiliary reagents (such as buffers) can preferably be used as propagation reagents. Preferred elongation substrates are nucleic acid building blocks or natural or artificial analogs or isomers or equivalents thereof. Agents are used as elongation substrates Construction of a counter strand of the nucleic acid to be detected are suitable. Nucleotides are preferably used as elongation substrates. Preferred nucleotides are dATP, dGTP, dCTP, dTTP and / or dUTP, dITP, iso-dGTP, iso-dCTP, deaza-dGTP and ATP, GTP, CTP, UTP and or ITP, deazaGTP, iso-GTP, iso-CTP. Equivalents are PNA monomers or PNA oligomers with or without positive and / or negative charge in the backbone and / or in the spacer. The elongation substrates can carry modifications as stated above.

In the case of PCR, particular preference is given to using mixtures of meta- or thermostable enzymatic DNA polymerase activities and mixtures of deoxyribo- and / or ribonucleotides and suitable auxiliary reagents as nucleic acid amplification reagents, for. B. Taq DNA polymerase in combination with dATP, dGTP, dCTP, dTTP and or dUTP and auxiliary reagents such as. B. salts and optionally detergents. In the case of RT-PCR, mixtures, complexes or domains of thermostable enzymatic reverse transcriptase and DNA polymerase activities and are particularly preferred as amplification reagents

Mixtures of deoxyribo- and ribonucleotides and suitable auxiliary reagents are used, e.g. B. mixtures of AMV or Mo-MLV reverse transcriptase or Tth-DNA polymerase in combination with dATP, dGTP, dCTP, dTTP and / or dUTP and ATP, GTP, CTP, UTP and auxiliary reagents such as. B. salts and optionally detergents.

In the thermocyclic multiplication reactions (e.g. PCR, RT-PCR) 2- or 3-phase cycles are carried out, preferably 2-phase cycles. In the 2-phase cycles, the strand separation of the nucleic acid amplification products is carried out at high temperature, preferably 85 ° C.-95 ° C., the common primer annealing and primer elongation at temperatures close to the melting point between primer and elongation counter strand, preferably between 52 ° C and 75 ° C. The strand separation is carried out by supplying energy and or enzymatically, preferably by elevated temperature, microwaves or the application of a voltage via a microelectrode, particularly preferably by elevated temperature. Up to 60 thermal cycles are carried out, preferably 32-42 cycles. In the isothermal propagation reactions (e.g. SDA) there is a continuous incubation at a medium temperature between 30 ° C and 70 ° C, preferably at 37 ° C - 45 ° C with enzyme mixtures, complexes or domains, or 60 ° C - 65 ° C with mesothermal enzyme mixtures, complexes or domains, in the case of SDA with z. B. mesothermal residual donations and DNA polymerases, e.g. B. from Bacillus stearothermophilus (e.g. BsoBI / Bst DNA-Pol exo); alternative enzymes are Ava I and Bca DNA-Pol exo. It is incubated for up to 2 hours, preferably 30-60 minutes. The multiplication reaction can take place in reaction vessels, capillaries or miniaturized reaction chambers, which can also be part of an integrated reaction chip.

If dUTP is used instead of or in addition to dTTP, DNA polymerase activity dUMP instead of dTMP is incorporated into the increased nucleic acid sequence or its complement. By incubation with the enzyme activity uracil-deglycosylase, preferably with a thermolabile embodiment of the enzyme activity, in which the renaturation after thermal denaturation of the enzyme activity takes place more slowly, the fragmentation of the amplification product and thus its property as nucleic acid amplification unit is possible. The UMP-containing amplification product can be incubated after the nucleic acid amplification and detection reaction (sterilization) and / or before a renewed nucleic acid amplification reaction (carry over prevention).

Alternatively, psoralen and / or isopsoralen and derivatives thereof and irradiation with UV light can also be used for the functional inactivation of the nucleic acid amplification product.

In the case of NASBA and TMA, mixtures, complexes or domains of enzymatic reverse transcriptase, DNA polymerase, RNase H and RNA polymerase and mixtures of deoxyribo- and ribonucleotides and suitable auxiliary reagents can preferably be used as nucleic acid amplification reagents, e.g. B. a mixture of AMV or Mo-MLV reverse transcriptase, possibly E. coli DNA polymerase, possibly E. coli RNase H and T7, T3 or SP6-encoded RNA polymerase or Mo-MLV reverse transcriptase and T7, T3 or SP6 RNA polymerase or corresponding mesostable enzymes, e.g. B. from Bacillus stearothermophilus in combination with dATP, dGTP, dCTP, dTTP and / or dUTP and ATP, GTP, CTP, UTP, and auxiliary reagents such as. B. salts and optionally detergents. The course of the propagation reaction in NASBA, TMA is isothermal.

The formation of the amplificates is detected with the probe, which binds to the binding sequence B of the amplicon to form a hybrid. The probe can act as a capture or detection probe. The ends of the probe binding sequence lie between the outer ends of the primer binding sequences. The probe can thus be hybridized with one strand of the amplificate.

The probe can be bound using known conditions. This is because the method according to the invention is a special embodiment of the so-called hybridization tests, the basic features of which are known to a person skilled in the art in the field of nucleic acid diagnostics. Insofar as experimental details are not given below, the full content of this is "Nucleic acid hybridization", publisher B.D. Harnes and S.J. Higgins, IRL Press, 1986, e.g. B. in Chapters 1 (Hybridization Strategy), 3 (Quantitative Analysis of Solution Hybridization) and 4 (Quantitative Filter Hybridization), Current Protocols in Molecular Biology, Ed. F.M. Ausubel et al., J. Wiley and Son, 1987, and Molecular Cloning, Ed. J. Sambrook et al., CSH, 1989. The known methods also include the chemical synthesis of modified and unmodified oligonucleotides and the selection of hybridization conditions by means of which a specificity can be achieved which depends, among other things, on the extent of the homology between the nucleic acids to be hybridized, their GC content and their length.

For this purpose, if the capture probe (in protected form) has not been added beforehand, the probe is added to the reaction mixture after the propagation reaction, preferably in the form of a solution. Reagent conditions are set which allow hybridization of the probe with an amplificate. The binding between the amplified nucleic acid sequence of the amplicon and / or its complement and the probe is preferably carried out at a constant temperature between 20 ° C and 75 ° C, preferably around 0 ° C - 30 ° C, particularly preferably around 0 ° C - 15 ° C below the melting temperature of the binding complex. The incubation time is up to 4 hours, preferably 15-120 minutes, particularly preferably 30-60 minutes. The binding with the amplificate and / or its complement takes place with or without a preceding denaturation step. The reaction without a preceding denaturation step is preferably carried out with PNA oligomers with or without negative and / or positive charges in the backbone and / or in the spacer at low salt concentrations.

When using several probes or multifunctional probes or probes which have several binding sequences for amplificates of different nucleic acids to be detected or their complements, several different amplificates or their complements can be bound. The formation of tripartite mini-amplicons, preferably of similar length, particularly preferably of such tripartite mini-amplicons of the same length, allows the setting of standardized incubation conditions for the formation of the different binding complexes in the nucleic acid amplification. This allows the parallel and / or sequential detection of several nucleic acid sequences in the context of multiplex methods. A multiplex amplification method is usually understood to be a method in which either different sequences on a nucleic acid (e.g. different regions of a gene) or different sequences on different nucleic acids, e.g. B. from different organisms, e.g. B. different viruses can be propagated simultaneously in an amplification mixture. Such methods place high demands on the reaction conditions, since the amplifications for the different sequences must have a similar amplification efficiency for a reliable evaluation. Eliminating one of the influencing factors for different efficiency is the subject of the present invention. In addition, the amplicon lengths preferably differ by no more than 20%, particularly preferably by no more than 5 nucleotides. In a special embodiment of the multiplex method according to the invention, amplicons of the different sequences are produced and the sum of the amplicons formed is then determined. A detection method is preferably used in which a marking can be used for all the detections; for example, all probes for the individual amplificates can be labeled identically, e.g. B. with the same ruthenium complex. This procedure is particularly advantageous for tests in samples from blood banks, since the type of infection is not important for the further usability of the samples for blood donations, but the sample is no longer suitable as blood donation material if any tested infection (e.g. B. HIV or HBV) is present.

In the multiplex amplification process, a distinction is made between real and spurious multiplex processes. In spurious methods, the primers are selected from highly conserved regions of the analyte nucleic acids in such a way that all of the nucleic acid sequences to be detected are amplified with the one set of (2) primers. In true multiplex processes, a mixture of more than 2 primers is used, of which at least 2 have a different selectivity. One or more of the primers can be specific for all or a subset of the nucleic acids to be detected. This method is particularly preferable when little-related sequences are to be amplified next to each other.

With multiplex methods, various combinations of nucleic acid sequences to be detected can be amplified next to each other, e.g. B. different subtypes of a virus or bacteria of different genera or species.

The detection of the binding complex formed between the amplificate and the probe can be carried out in methods known to the person skilled in the art, in particular in various embodiments, namely direct detection methods, such as, for example, B. with spectroscopic or physical methods, by sequencing or by heterogeneous or homogeneous detection formats.

Direct spectroscopic or physical methods are e.g. B. melting temperature determinations, addition of intercalating or nucleic acid binding Dyes or metal atoms or particles, mass spectroscopy, surface plasmon resonance or fluorescence-coupled surface plasmon resonance, or E-wave measurements.

The sequenced tripartite mini amplicon can be sequenced via binding of the primer and subsequent enzymatic sequencing according to Sanger. For the detection of the sequencing products, either the primer or the chain termination reagents are preferably labeled. The sequencing products can also be detected using mass spectroscopy. When only limited types of nucleotides are added, corresponding to the flanking nucleotides at the end of the primer, mini-sequencing is possible, which is particularly advantageous for the analysis of polymorphisms.

With the heterogeneous detection methods, the probe can be used either as a capture probe or as a detector probe, depending on the modification made. When using multiple probes, multiplex formats can be implemented.

When using the probe as a capture probe, the probe can either be covalently bound to the solid support or prebound via a binding pair and the formation of the

Binding complex between the amplificate and the probe takes place on the solid support. In this embodiment, in addition to solid supports that contain one type of probe, solid supports that contain several or a plurality of types of probes can also be realized, such as, for. B. probe beads or particles (so-called beads), probe test strips, probe panels or probe arrays on solid supports or miniaturized chips, which in turn can also be part of integrated reaction chips. These carrier-bound detection systems are particularly suitable for multiplex formats. In a preferred embodiment, the complex between the amplificate and capture probe is first pre-formed in solution and then applied to the solid support. For this purpose, the amplicon preferably contains an immobilizable group I which can bind to a group R located on a solid phase.

The type of solid phase depends on the group I which enables immobilization. It preferably has an immobilizing group R which can have a binding interaction with I. For example, the immobilizable group a hapten, then a solid phase can be used which has antibodies against this hapten on its surface. Is the immobilizable group a vitamin, such as. B. biotin, then the solid phase can contain binding proteins such as avidin or streptavidin immobilized. Particularly preferred residues I and R are biotin and streptavidin. Immobilization via a group on the modified

Nucleic acid is particularly advantageous because it can take place under milder conditions than, for example, hybridization reactions. To immobilize the nucleic acids formed, the reaction mixture is preferably filled into a vessel before, during or after the formation of the nucleic acid hybrids, the surface of which can react with the immobilizable group. It is possible to use a solid phase in the form of a porous material, such as a membrane, a fabric or a nonwoven, to which the reaction mixture is applied. Likewise, the use of beads, so-called beads - z. B. magnetic particles or latex particles - possible. The vessel is preferably a cuvette, a tube or a microtiter plate. The solid phase should have at least as many binding sites for the immobilizable group of the probe as there are nucleic acid hybrids and thus nucleic acids to be detected. The preparation of a preferred solid phase is described in EP-A-0 344 578, to which reference is made in full.

For the heterogeneous detection reactions, the liquid phase is removed from the vessel, the porous material or the pelleted beads after the incubation period during which the immobilization reaction takes place. The solid phase can then be washed with a suitable buffer, since the binding of the hybrids to the solid phase is very efficient. The detection of the bound binding complexes can be carried out via the built-in during the nucleic acid sequence amplification reaction

Detection modification in the primer and / or a nucleotide and / or the probe is carried out with the aid of known direct or indirect detection types for these modifications according to the prior art.

In the case of directly detectable groups, for example fluorescent labels, the amount of labeling can be determined fluorometrically. The detectable group is indirect detectable e.g. B. a hapten, the modified nucleic acid is preferably reacted with a labeled antibody against the hapten, as described analogously in EP-A-0 324 474. The label on the antibody can be, for example, a color or fluorescent label or, preferably, an enzyme label, such as β-galactosidase, alkaline phosphatase or peroxidase. In case of

Enzyme labeling is the amount of nucleic acid measured by mostly photometric, chemiluminometric or fluorometric monitoring of a reaction of the enzyme with a chromogenic, chemiluminogenic or fluorogenic substrate. The measurement signal is a measure of the amount of originally present nucleic acid to be detected and thus possibly of organisms to be detected.

In a preferred embodiment, the increased tripartite mini amplicons are bound by nucleic acid capture probes or PNA capture probes, which are covalently immobilized on micro titer plates or magnetic particles. In this preferred embodiment, the detection takes place after formation of the binding complex and washing via a biotin modification of one or both primers in the amplificate by addition of avidin-horseradish peroxidase and a mixture of TMB / TMF color substrates.

In a further preferred embodiment, a digoxigenin detection marker is incorporated via one of the nucleotides of the nucleic acid amplification reaction. The binding complex between the amplificate and a biotin-labeled nucleic acid capture probe or PNA capture probe is bound to the surface of a streptavidin-coated reaction vessel. After washing, anti-digoxigenin-horseradish-peroxidase-antibody conjugates are added and the color is verified using the ABTS color substrate.

In a further preferred embodiment, the detection of one or more amplified products after binding is carried out by one or more different covalently (e.g. anthraquinone: UV light coupling or gold surface: SH coupling) or coordinatively (e.g. biotin: Streptavidin) bound capture probes, by washing and by detection of a fluorescent or chemiluminescent signal that either was excited directly by primary light or via surface plasmon resonance or E-wave, with the help of z. B. CCD cameras or confocal fluorescence scanners.

When using the probe as a detection probe, the probe can bind to the solid phase either simultaneously, before or after binding of the amplificate. In this case, the amplificate is bound to the solid phase via modifications which have been incorporated via one or both primers or via the incorporated nucleotides. It is then washed and detected.

In a further embodiment, the complex between the amplificate and the detection probe is first pre-formed in solution and then applied to the solid support and washed. The detection of the solid phase-bound binding complexes between the amplificate and the detection probe takes place via the detection modification of the probe with the help of known direct or indirect detection types for these modifications according to the state of the art.

In a preferred embodiment, ruthenium chelates are added to the amplificates which contain biotin modifications via one or both primers

Detection probes bound. The detection probes are either ruthenium-labeled oligonucleotides or ruthenium-labeled PNA oligomers. After formation of the binding complex between the ruthenium-labeled detection probe and the biotin-labeled amplificate, the complex is bound to streptavidin-coated magnetic particles, transferred to a measuring cell, attached to an electrode within the measuring cell and generation and measurement of an electochemiluminescence signal.

In a further preferred embodiment, the detection probe is labeled with digoxigenin. After formation of the binding complex between the digoxigenin-labeled detection probe and the biotin-labeled amplificate, the complex is bound by a capture probe which is covalently immobilized on a microtiter plate or on magnetic particles. In this preferred embodiment, the detection takes place after formation of the binding complex and washing via a biotin modification of one or both primers in the tripartite mini amplicon by addition of avidin-horseradish peroxidase and a mixture of TMB / TMF color substrates. When using homogeneous reaction formats, detection probes are used which contain either quenched fluorescent labels, internal base substitutions with double-strand complex-activatable fluorescent dyes or terminal energy donors or acceptors (in combination with corresponding energy donors or acceptors on adjacent primer or E) - Wear probe ends: energy transfer complexes). In these cases, the detection probe is added during the nucleic acid amplification. In the case of the quenched fluorescent labels, fluorescence is activated by dequenching after binding the detection probe to the resulting tripartite mini amplicon and exonucleolytic degradation and release of the fluorescent dye-modified nucleotide. In the case of internal base substitutions, the fluorescence signal is generated by forming the binding complex between the detection probe and the tripartite mini-amplicon that forms. In the case of the energy transfer complexes, a fluorescence signal is formed by adjacent attachment of the labeled primer and the labeled probe. The

The resulting fluorescence signals are preferably measured by real-time measurements.

In a particular embodiment, fluorescein and rhodamine or derivatives thereof are used as fluorescence and quencher components in the quenched detector probes. In a further embodiment, ruthenium or rhenium chelates and quinones or derivatives thereof are used as electrochemiluminescent and quencher components in the quenched detector probes. In a further particular embodiment, anthraquinone or derivatives thereof are used as internal base substituents of the detector probe. In a further embodiment, Cy-5 and fluorescein or derivatives thereof are used as energy transfer components. In a special embodiment, cyanine dyes such. B. SYBR Green or acridine dyes used.

For the purposes of this first aspect of the invention, those embodiments are particularly preferred in which at least one of the binding sequences of the primers and the probe is not specific for the nucleic acid to be detected. Specific in the sense of The invention is a sequence if, based on a continuous sequence of nucleobases, it would in principle be able, under stringent conditions, to bind only with a sequence on the nucleic acid to be detected, but not with nucleic acids of other, undetectable organisms or species or groups of organisms. A sequence is preferably not specific for a sequence if it could hybridize with other nucleic acids under the conditions which are set for carrying out the detection.

Regardless of the first aspect of the invention described so far, a general object of the invention is a method for the specific detection of a nucleic acid comprising the steps of producing a multiplicity of amplificates of a section of this nucleic acid with the aid of at least two primers, bringing the amplificates into contact with a probe which is attached to the Can bind amplificate, and detection of the formation of a hybrid from the strand of the amplificate and the probe, characterized in that at least one of the primers is not specific for the nucleic acid to be detected. In this case, region B can contain nucleotides which do not belong to the binding sequence E. Here too, however, the binding sequences of the primers and the probe can overlap.

Homologies to other genomes (sequences) can be identified with the help of a defined starting sequence. A z is used. B. on the Internet for everyone accessible search engine with the name "BLAST" (Basis Local Alignment Search Tool) (homepage address:> http://www.ncbi.nlm.nih.gov/BLAST/ <).

This enables access to various other sequence and protein databases, the most important of which are:

GenBank, EMBL, DDJB, PDB, PIR and Swiss-Prot.

BLASTN methods according to Altschul et al. (1990) J. Mol. Biol. 215: 403-410 used in the context of UWGCG search methods.

The search methods are also based on sequence databases such. B. the EMBL sequence databases, preferably also viral sequence databases such. B. em-vrl applied. The Blast program offers the user numerous customization options in order to be able to carry out an individual search, ie to identify those sequences which are specific for one or more analytes or which are not specific, ie also occur in other organisms or not. Reference is also made to Altschul, Stephen F., Warren Gish, Webb Miller, Eugene W. Myers, David J. Lipman (1990). Basic local alignment search tool. J. Mol. Biol. 403-410. Surprisingly, the selectivity of the detection method does not only result from the selectivity of the individual primers for a specific target, but from the cumulative selectivity of the overall system. So even two primers or two primers and one probe, individually, can be completely unselective, ie individually with one

Hybridize a variety of targets; the fact that the selectivities of the individual primers and probes (only) overlap in the nucleic acid to be detected, there is an overall specificity. Because the selectivity of the primers is not so much determined when selecting the nucleic acid to be amplified and detected, it is much better possible to localize short amplicons for different targets that are complete or extensive in their length (ie over 95%) agree. This makes simultaneous amplifications and hybridizations (as in the case of nucleic acid probe arrays) more feasible and reproducible.

The invention also relates to a reagent kit for carrying out this method. This contains the primers and preferably also a detection probe. However, other reagents such as buffers and enzymes, e.g. B. contain a polymerase.

In a further embodiment, the primers contain further sequences at their 5 'end. These sequences are between 1 and 100, particularly preferably between 5 and 80 nucleotides long. So far, it has not been common to choose oligonucleotides with a length of more than 40 nt as primers. In one embodiment, these sequences are chosen such that they cannot hybridize with the nucleic acid to be detected on the primer binding site but on another, not to be detected. It is even possible to choose them so that they are complementary to the sequences that are not on the binding site of the same primer on one Connect the nucleic acid to be detected. So if the primer can also bind to a human genome, the sequences can also be human. It is possible to modify one or both of the primers accordingly. The additional sequences are not so long that they prevent hybridization of the primers with the binding sequences on the nucleic acid to be detected, for example the HCV genome. The additional sequences can also be chosen such that they hybridize more firmly with short partial sequences of the primers in the primer binding site than they bind with other sequences in the primer binding site. In this way, secondary structures within the primers can be resolved and the binding ability of the primers with the nucleic acid to be detected can be improved.

Another way to specifically make primers and probes non-selective is to use degenerate bases within the sequence. The region in which the hybridization of the target nucleic acid with the primer or the probe is to take place is expediently chosen in such a way that there are relatively few differences between the target sequence and another sequence which cannot be detected (e.g. another microorganism). The differences that still exist can be largely compensated for by using degenerate bases at the different base positions. Differences in primers (A and G) can be achieved by incorporating the base P (6H, 8H-3,4-dihydro-pyrimido [9,5-C] [1,2] oxazin-7-one, e.g. B. Nucleic Acids Research, Vol. 17, 24, 1989, p. 10373-10383). The same applies to pyrimidines with the base K (Nucleorides & Nucleotides, 16 (7-9), 1507-1511 (1997)). Even greater degeneration is possible through the use of inosine (US Pat. No. 5,585,477; US Pat. No. 5,691,134; US Pat. No. 5,578,467; J.Biol.Chem. 260, 5, 2605-2608, 1985; Nucl.Acids Res 1995, 23, 13, 2499-2505), since inosine allows base pairing with all four bases.

Another option for using non-complementary bases is to replace A with D (diaminopurine or / and replace C with M (methylcytosine).

In a further embodiment, the 5 'end of one primer and the 5' end of the other primer are covalently linked to one another. Two different embodiments are conceivable here. In a first embodiment, the forward and reverse primers are linked to one another for the amplification of the same analyte. The result of the amplification is therefore a large number of constructs in which two different amplification strands are covalently linked to one another. As a by-product, which, however, also

The proof can be based on products in which only one of the two primers (parts) is extended.

In a wide embodiment, the two linked primers are intended for the amplification of different nucleic acids to be detected (e.g. one for HBV, the other for HGV). The appropriate reverse or forward primers must then be added for the amplification. The 5 'ends of the primer sequences can be linked to one another directly or via a linker. Any type of molecule can be used as a linker, since it is not important to adhere to a specific nucleic acid, the spacing of the bases on a nucleic acid to be detected. However, the linker is preferably not so hydrophobic that the solubility of the conjugate is impaired too much. The linker preferably contains one or more nucleotide sequences which are not directly complementary to the corresponding or other sequences on the nucleic acid (s) to be detected. At least one of the sequences which meet the conditions for the additional sequences of the (monofunctional) primers described above is particularly preferred.

These (bifunctional) primer conjugates are also suitable for multiple (at least duplex) determinations of analyte nucleic acids. In principle, these conjugates can be prepared in a known manner, although it is preferred to first synthesize the still protected individual sequences chemically, then to activate one end of one individual sequence and to deprotect one end of the other individual sequence. The coupling reaction can proceed relatively automatically through the activation group or can be accelerated by activation reagents. However, the conjugate is particularly preferably chemically synthesized by continuous sequential extension on a solid phase, without intermediate detachment therefrom. For this purpose, the first partial sequence can first be synthesized with 3'-phosphoramidites as usual. From the point of attachment (5'-5'-link) a 5'-phosphoramidite is used instead of the 3'-phosphoramidite. This leads to a reversal of the polarity within the conjugate. The reaction sequence is shown by way of example in FIG. 5, the associated reagents in FIG. 6.

Preferably, the primers bind to the binding sequences A or C, as described above, and the probe to a region B between the ends of the binding sequences A and C or the complement thereof.

Even if at least one sequence from the 3 binding sequences of the two primers and the probe is not specific for the nucleic acid to be detected, the overall specificity of the detection method is retained. If one of the primer sequences is not specific for the nucleic acid to be detected, but also binds to other nucleic acids, no specific nucleic acid amplification product can be formed on the other nucleic acid, since the second primer binding sequence on this nucleic acid is missing. Unspecific nucleic acid amplification products on the other nucleic acid are not detected if the specific binding sequence for the probe is missing. If the second primer sequence is also not specific for the nucleic acid to be detected, a specific nucleic acid amplification product can only be formed on the other nucleic acid if both primer binding sequences are in the same nucleic acid amplification unit. This nucleic acid amplification product is also not detected because the specific binding sequence for the probe is missing. If the probe sequence is not specific for the nucleic acid to be detected, but the two primers are specific, none will be

Nucleic acid amplification products of the other nucleic acid are formed. If, in addition to the probe sequence, one of the two primer sequences is also not specific for the nucleic acid to be detected, no specific nucleic acid amplification product of the other nucleic acid can be formed. Nonspecific nucleic acid amplification products of the other nucleic acid that may be are formed, contain other sequences in the probe binding area and are therefore not detected. If all three binding sequences for the two primers and the probe are not specific for the nucleic acid to be detected, no nucleic acid amplification product is formed if at least one of the two primer sequences is not in a nucleic acid amplification unit of the other nucleic acid. If the probe sequence is not in the nucleic acid amplification unit of the two primer sequences for the other nucleic acid, a specific nucleic acid amplification product of the other nucleic acid can be formed, but it cannot be detected. The only case that a specific nucleic acid amplification product of the other nucleic acid can be formed and detected is when all three sequences lie within a nucleic acid amplification area. However, this can be avoided by selecting the appropriate sequence of the nucleic acid amplification unit, e.g. B. by not selecting the primer hybridization sites simultaneously from the same locus of the same undetectable organism.

In a further embodiment, the amplificates are produced using nucleotides, particularly preferably mononucleotides, which are in each case complementary to A, G, C and or T. Region B or B 'of the nucleic acid to be detected preferably contains all 4 natural nucleobases.

In a further embodiment of the novel method, partial components (primers or probes) of the different primer-probe combinations can be identical for the different nucleic acids to be detected. As a result, the determination of several nucleic acid targets, eg. B. possible for different viruses such as HBV, HIV and HCV with a single amplification reaction (multiplex amplification). A technical advantage of the method according to the invention is that a high degree of agreement of the measured values is achieved with multiple determinations of a sample.

In the following, the two aspects of the present invention will be described on the basis of evidence for HCV. The nucleic acid sequence of HCV is described for example in EP-B-0 318 216. The sequences of those involved Components are shown in Figure 4. The method according to the invention enables the highly specific and highly sensitive detection of virus nucleic acids such as. B. HCV RNA from the 5 'untranslated region of the HCV genome in a copy number of 10 copies per test with a dynamic range of 10 ⁵ , due to an improved signal-to-noise ratio. This is surprising since primers and probes can be used in the test which have a primer / probe design which is not preferred for the person skilled in the art, namely e.g. B. sequence sections that tend to form primers-dimers, or base mismatches near the 3 'end. The short probe has a melting point close to the test temperature, so that the person skilled in the art would not have expected stable binding of the probe to the nucleic acid amplification product. In the previous tests with the longer, five-part nucleic acid amplification products, an increase in specificity and sensitivity has so far not been attempted by shortening, but rather by extending the primer probe sequences and / or the nucleic acid amplification product with the signaling components.

In spite of the short, increased sequence of the nucleic acid to be detected, the detection of HCV-RNA is surprisingly also possible specifically and reproducibly in positive HCV plasma samples in which the HCV-RNA was not pre-cleaned in a sequence-specific manner, but was used directly from lysed and concentrated plasma samples over glass surfaces. HCV-negative plasma samples give no signal. This is surprising in that the HCV RNA genome is very labile to fragmentation in plasma lysates. With z. B. HIV plasma samples, HBV serum samples, Chlamy slide samples from urine or human DNA samples from whole blood, which were also concentrated over glass surfaces, no signal is also obtained with the primers and probes used.

The method according to the invention can be used to avoid one or more of the disadvantages described for the prior art or to realize one or more of the following advantages. The PCR cycles can be much shorter. This can shorten the total time of the verification procedures. The sensitivity of the detection can be increased because there is less competition / displacement can take place between the short counterstring of the amplicon and the detector probe. The specificity of the detection is increased because the relative proportion of the internal detector region is increased compared to the total amplicon length. The differentiability of subtypes can be increased. The detection background can be reduced because short amplicons have less potential for unspecific hybridization. For this reason, the signal-to-noise ratio can be increased. The reproducibility of the results can be increased since smaller target regions on RNA genomes are less sensitive to RNA degradation. The possibilities for the formation of secondary structures are reduced.

The invention is illustrated by the following examples:

General

All oligonucleotides used are linear and single-stranded.

example 1

Detection of HCV from human blood

a) Sample preparation:

RNA was isolated from plasma using the following sample preparation protocol:

I. Mix plasma (420 μl) with 80 μl Proteinase K (25 mg / ml) and vortex for a few seconds 2. Add 500 μl lysis buffer (incl. 1 μg Camer-RNA (polyA) / ml): 5.4 M

Guanidinium thiocyanate; 10 roM urea; 10 mM Tris-HCl; 20% Triton X 100; pH 4.4

3. vortex and then shake at RT for 10 min

4. Add 500 μl isopropanol MGP (6 mg magnetic glass particles in isopropanol)

5. vortex and then shake at RT for 20 min

6. Magnetic separation of the MGPs

7. Remove and discard the supernatant

8. Add 750 µl wash buffer: 20 mM NaCl; 20 mM Tris-HCl pH 7.5; 70% ethanol

9. Resuspend MGPs on vortex and re-magnetic separation

10. Repeat the washing process a total of 5 times

I I. Add 100 μl of DEMC water for elution 12. Shake at 80 ° C for 15 min 13. Magnetic separation

14. Insert 10 μl of the eluate into the RT-PCR

b) Cloning and preparation of the RNA standard:

The wild-type standard "pHCV-wt" was first amplified by amplifying a section of the HCV genome with the primers KY80 (5 '-gcagaaagcgtctagccatggcgt-

3 ', SEQ.ID.NO.l) and KY78 (5'-ctcgcaagcaccctatcaggcagt-3', SEQ.ID.NO.2) and then the amplicon via a so-called "blunt-end" cloning into the vector pBluescript SK + cloned. After the bacterial cells had multiplied, the plasmid was isolated, linearized by restriction enzyme digestion and the corresponding RNA fragment obtained and purified by in vitro transcription.

The RNA was quantified by photometric measurement of the absorption at 260 nm.

All of the molecular biological methods described here can be found in relevant methodology books (eg Maniatis et al .; Ausubel et al.).

c) RT-PCR assay:

The amplification was carried out with the Reagents and after Cycler protocol:

Final reagent concentration in the master mix

5 x RT-PCR buffer 1 x

MnOAc 2.5 mM

Tth polym. 10 u dNTP mix 200 μM (dATP, dCTP, dGTP) / 600 μM (dUTP)

UNG 2u

Primer forw. HC2F 0.3 μM (5 ^' -agtatgtgtgtcgtgcagcc-3', SEQ.ID.NO.3)

Primer rev. HClF-bio 0.3 μM (5'bio-tggctctcccgggagtgg-3 ', SEQ.ID.NO.4)

The amplification was carried out according to the following cycler protocol: 10 min 37 ° C decontamination by UNG 30 min 60 ° C reverse transcription 1 min 95 ° C denaturation

Final reagent concentration in the master mix

35 cycles:

15 sec 94 ° C denaturation

20 sec 56 ° C primer annealing and elongation

7 min 72 ° C elongation hold 50 ° C

d) detection:

The entire detection reaction was fully automated on an Elecsys® 1010 automatic analyzer (Boehringer Mannheim GmbH). Brief description:

1. Removal of 10 μl amplificate and 35 μl denaturing solution (BM-Id-No. 1469053)

2. Incubation in a reaction vessel for 5 min at 37 ° C 3. Add 130 μl of hybridization solution BM-Id-No. 146 9045 mixed with 25 ng / ml ruthenium-labeled probe

4. Incubation for 30 min at 37 ° C

5. Add 35 μl of an Elecsys® SA Magnetbeadlsg. (BM-Id-No. 171 9556) 6. Incubation for 10 min at 37 ° C

7. Measurement of the electrochemiluminescence of 120 μl of the reaction mixture in the Elecsys® 1010 measuring cell

Two different ruthenium-labeled probes were used for hybridization:

PNA probe: Ru- (Ser) ₂ -TCCAGGACCC-Ser-Gly

DNA probe: 5'-Ru-CTCCAGGACCCC-3 ', SEQ.ID.NO.5

Example 2

Determination of the analytical sensitivity using an RNA standard dilution series

10 ¹ , 10 ² , 10 ³ , 10 ⁴ and 10 ⁵ copies of HCV-RNA standard were amplified in duplicate determinations. An HCV-negative plasma, an HCV-positive plasma (after sample preparation) and water served as controls. After amplification, all samples were measured (ECL detection, Elecsys® 1010).

Result (units x 100):

• The use of the primers HC2F / HC IF-bio leads to a very good one

Amplification in RT-PCR, measured at the signal level: The entire detection area of the Elecsys® is used (approx. 5 log levels).

• There is a very good signal gradation within the dilution series

• The background, measured in terms of HCV-negative plasma and water, is relatively small

»Both PNA and DNA can be used as a probe Example 3

Review of HCV assay specificity

For this purpose, different starting nucleic acids (human genomic DNA; HIV-RNA, HBV-DNA, Chlamydia-DNA) with the above-mentioned Primers and probes tested. HCV plasma served as positive control and HCV negative plasma and water as negative control.

Result (units x 100):

• Both probes used (PNA, DNA) only give a signal in the ECL measurement with their associated analyte. This means: No detectable non-specific amplifications with the primers and probes used. Example 4

Checking the probe specificity

For this experiment, different amplificates of other analytes with the respective specific primers were prepared and then against the above. PNA and DNA probes hybridized. The amplifications that were carried out were checked with the respective associated analyte probe.

Result (units x 100): (each mean from double determination)

• The control reactions (HIV, HBV, Chlamydia) provide clear evidence of the amplificate with the appropriate probe.

• The PNA and DNA probes used only give a specific signal with HCV.

• There are no non-specific hybridizations of the PNA DNA probes with other amplificates. Example 5

Synthesis of a 5'-5 'linked oligonucleotide (3' - (Primer-1) -5'-5 '- (Primer-2) -

3 '

The 5 '-5' -linked oligonucleotide is synthesized on a DNA Synthesizer Model 394A from Applied Biosystems with the standard 1 μmol synthesis cycle recommended by Applied Biosystems. It becomes a synthesis column which contains 1 μmol of a carrier material (1) functionalized with the corresponding 5'-O-DMT protected starting nucleoside (available from Applied Biosystems) and 5'-O-DMT-3 'phosphoramidite (2) (available from Applied Biosystems) for the primer 1 sequence and 3 '-O-DMT-5' phosphoramidite (3) (available from Eurogentec / Glen Research) for the primer 2 sequence . The synthesizer is used with the synthesis reagents recommended in the ABI Manual (bottle # 1-4 = 5'-O-DMT-3'-phosphoramidite 2 (0.1 M in MeCN), # 5-8 = 3 '-O-DMT-5 '-Phosphoramidite 3 (0.1 M in MeCN), # 9 activator: tetrazole (0.5 M in MeCN), # 10 concentrated ammonia pA, # 11 Cap A: Ac ₂ O / pyridine / THF, # 12 Cap B: N-methylimidazole / THF, # 14, TCA in DCM (2%), # 15 oxidation reagent: I ₂ / H ₂ O / pyridine / THF, # 18 MeCN, # 19 DCM) (all available from Applied Biosystems). The course of the synthesis is detected via regular trityl value determinations on the synthesizer (autoanalysis). After the synthesis cycle is complete, the automatic carrier elimination closes with conc. Ammonia. The cleavage solution is fed into a special cleavage vessel on the synthesizer. This is then heated in a water bath at 56 ° C. for 5 hours in order to remove all protective groups. After cooling, the solution is rotated in on a rotary evaporator. The oligonucleotide is purified by preparative anion exchange HPLC on a Protein-Pak DEAE 8 HR 10 x 100 mm column (Waters) with 25 mM Tris / HCl, 1 mM EDTA, 0-0.6 M NaCl, pH 8.5 as elution buffer. The analysis is carried out using a Gen-Pak FAX 1.6 x 100 mm anion exchanger HPLC column from Waters. The product fractions are desalted by dialysis (MWCO 1000 from Spectrapore). The desalted oligonucleotide solution is spun in, in dissolved in sterile water, filtered through a sterile 0.2 μm filter and the concentration determined by UV spectroscopy at 260 nm. Yield: 75 OD

Example 6: Alternative primer and probe combinations

Alternatively, primers and probes from the following primer and probe regions can be used:

Forward primer: selected from the sequence between positions 390 and 417, reverse primer: selected from the sequence between positions 421 and 448, probe: selected from the sequence between positions 391 and 440, all based on the HGBV-B sequence the sequence HG22304 available from the EMBL database em-vrl, or from Proc. Natl. Acad. Be USA 1995, 92, 3401-3405 and / or from J. Virol. 69: 5621-5630. The sequence shown in FIG. 7 corresponds to positions 390 to 448 of this sequence, so that the primer and probe positions can be converted directly.

Preferred primer / probe combinations result as follows: forward primer selected from one of the sequences: 390-406, 390-408, 391-406, 391-408, 392-406, and 392-408, reverse primer selected from one of the sequences: 427-448, 427-447, 427-446, 428-

448, 428-447, 428-446, 429-448 and 429-447, probe selected from one of the sequences: 402-412, 401-413, 400-414, 399-415, 398- 415, 397-415, 396 -415, 395-415, 394-415, 393-415, 392-415, 391-415, 408-436, 408-435, 408-434, 408-433, 408-432, 408-431, 408-430 , 408-429, 408-428, 409-

436, 409-435, 409-434, 409-433, 409-432, 409-431, 409-430, 409-429, 409-428, 410-436, 410-435, 410-434, 410-433, 410-432, 410-431, 410-430, 410-429, and 410-428, or, preferably:

forward primer: sequence of 390-406, 390-408, 391-406, 391-408, 392-406, and 392-408, reverse primer: selected from one of the sequences: 423-448, 423-447, 423-446, 423-

445, 423-444, probe: selected from one of the sequences: 402-412, 401-413, 400-414, 399-415, 398-

415, 397-415, 396-415, 395-415, 394-415, 393-415, 392-415, 391-415, 409-433, 409-432, 409-431, 410-433, 410-432, , 410-431, 410-430, 410-429, 410-428, 409-

430, 409-429, 409-428, 408-433, 408-432, 408-431, 408-430, 408-429, and 408-

428 or, particularly preferred:

forward primer: sequence of 390-406, 391-406, and 392-406, reverse primer selected from one of the sequences: 423-448, 423-447, 423-446, 423- 445, 423-444,

Probe: selected from one of the sequences: 402-412, 401-413, 400-414, 399-415, 398- 415, 398-415, 397-415, 396-415, 395-415, 394-415, 393- 415, 392-415, 391-415, 409-433, 409-432, 409-431, 410-433, 410-432,, 410-431, 410-430, 410-429, 410-428, 409-430 , 409-429, 409-428, 408-433, 408-432, 408-431, 408-430, 408-429, and 408-428.

All of these sequences are taken from the HGBV-B genome and therefore do not hybridize selectively to HCV.

Example 7:

Detection of HIV

An HIV-positive plasma with an initial concentration of 15000 genome equivalents (geq) HIV per ml was used as the starting material. This plasma was successively diluted by a factor of 10 in negative plasma and, after sample preparation, was amplified in duplicate with the corresponding primer pairs. HIV-negative plasma and water served as controls. To determine the specificity, an HBV and an HCV-positive plasma were also processed. After amplification, all samples were measured (ECL detection, Elecsys® 1010). Primers and probes used:

Note: SK and RAR are published Röche Primer / Probes, GH-AI to GH-A6 are new MCR primers from the pol region of the HIV genome -> 3 -

Amplification mix and Thermocvcler protocol master mix:

Reagents final conc. in master mix

5x bicine buffer lx

MnOAc 2.5 mM dNTPs (incl. DUTP) 200μM / 600μM forward primer 0.3 μM reverse primer 0.3 μM

(biotinylated)

Tth polymerase 10 units

UNG 2 units

Total volume: 100 μl

PCR cycling:

10 min 37 ° C UNG decontamination

30 min 60 ° C reverse transcription

30 sec 95 ° C denaturation

5 cycles 15 sec 95 ° C denaturation

20 sec 50 ° C annealing / elongation

0 cycles 15 sec 94 ° C denaturation

20 sec 60 ° C Ajinealin-i / elongation

7 min 72 ° C elongation

50 ° C

Result (ECL-counts x 100):

There is a very good signal gradation within the dilution series Example 8: Detection of HBV

10 ° were amplified in duplicate determinations. 10 ', 10 \ 10 ³ , 10 ⁴ and 10'

Genoma equivalents (geq) HBV. HBV-negative plasma and

Water. After amplification, all samples were measured (ECL detection, Elecsys®

1010).

HBV-positive plasma sample preparation was carried out analogously to the sample preparation described for HCV.

Primers and probes used:

Note: Ref. Are reference primers. Number 1 -5 the new MCR-HBV-Pπmer. Amplification mix and Thermocvcler protocol

Master mix:

Reagents final conc. in master mix lOx PCR buffer lx

MgCl ₂ 3 mM dNTPs (incl. DUTP) 200μM / 600μM forward primer 0.3 μM reverse primer 0.3 μM

(biotinylated)

Taq polymerase 2.5 units

UNG 2 units

Total volume: 100 μl

PCR cycling:

10 min 37 ° C UNG decontamination 10 sec 95 ° C denaturation

5 cycles 10 sec 55 ° C annealing 10 sec 72 ° C elongation 10 sec 90 ° C denaturation

30 cycles 10 sec 60 ° C Annealing 10 sec 72 ° C elongation 50 ° C

The detection was also carried out analogously to the detection described for HCV.

Result (ECL-counts x 100):

• The signals of the MCR primers show a significantly improved dynamic compared to the reference

• There is a very good signal gradation within the line of digestion

• The background, measured in terms of HBV-negative plasma and water, is relatively small

SEQUENCE LOG

(1) GENERAL INFORMATION: (i) APPLICANT:

(A) NAME: Boehringer Mannheim GmbH (B) STREET: Sandhoferstr. 116

(C) LOCATION: Mannheim

(E) COUNTRY: DE

(F) POSTAL NUMBER: 68305

(G) TELEPHONE: 0621 759 4348 (H) TELEFAX: 0621 759 4457

(ii) DESCRIPTION OF THE INVENTION:

Specific and sensitive nucleic acid detection procedure (iii) NUMBER OF SEQUENCES: 5 (iv) COMPUTER READABLE VERSION: (A) DATA CARRIER: floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS / MS-DOS

(D) SOFTWARE: Patentin Release # 1.0, Version # 1.30 (EPA)

(2) INFORMATION ON SEQ ID NO: 1: (i) SEQUENCE LABEL:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleotide

(C) STRAND FORM: Single strand

(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: Other nucleic acid

(A) DESCRIPTION: / desc = "oligodeoxyribonucleotide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GCAGAAAGCG TCTAGCCATG GCGT 24 (2) INFORMATION ABOUT SEQ ID NO: 2: (i) SEQUENCE LABEL:

(A) LENGTH: 24 base pairs

(B) TYPE: Nucleotide (C) STRAND FORM: Single strand

(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: Other nucleic acid

(A) DESCRIPTION: / desc = "oligodeoxyribonucleotide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CTCGCAAGCA CCCTATCAGG CAGT 24

(2) INFORMATION ABOUT SEQ ID NO: 3: (i) SEQUENCE LABEL: (A) LENGTH: 21 base pairs

(B) TYPE: nucleotide

(C) STRAND FORM: Single strand

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: Other nucleic acid (A) DESCRIPTION: / desc - "oligodeoxyribonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

AGTTATGTGT GTCGTGCAGC C 21

(2) INFORMATION ABOUT SEQ ID NO: 4: (i) SEQUENCE LABEL:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

(C) STRAND FORM: Single strand (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid (A) DESCRIPTION: / desc = "oligodeoxyribonucleotide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TGGCTCTCCC GGGAGTGG 18 (2) INFORMATION ABOUT SEQ ID NO: 5: (i) SEQUENCE IDENTIFIER:

(A) LENGTH: 12 base pairs

(B) TYPE: nucleotide

(C) STRAND FORM: Single strand (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(A) DESCRIPTION: / desc = "oligodeoxyribonucleotide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CTCCAGGACC CC 12

Claims

claims

1. A method for the detection of a nucleic acid comprising the steps

Production of a multiplicity of amplificates of a section of this nucleic acid with the aid of two primers, one of which can bind to a binding sequence (A) of a strand of the nucleic acid and of which the other to a binding sequence C which does not overlap with A in FIG. 3 'Direction of A located sequence C is essentially complementary, can bind,

Contacting the amplificates with a probe with a binding sequence D which can bind to the sequence B between the sequences A and C or the complement thereof, and

Detection of the formation of a hybrid from an amplificate and the probe,

characterized in that the sequence located between the binding sequences A and C contains no nucleotides which do not belong to the sequence region E formed from the binding sequence D of the probe and the sequence of the amplificate bound therefrom.

2. The method according to claim 1, characterized in that the binding sequence D of the probe overlaps with one or both binding sequences of the primers.

3. The method according to any one of the preceding claims, characterized in that at least one of the primers has on its non-extendable part nucleotides that are not directly with the nucleic acid to be detected or its

Hybridize complement.

4. The method according to any one of the preceding claims, characterized in that at least one of the binding sequences is not specific for the nucleic acid to be detected.

5. The method according to any one of the preceding claims, characterized in that the total length of the binding sequences from that of the binding sequence Part of the probe-pointing part of the binding sequence of one primer up to the part of the other primer which also points away from the binding sequence of the sample is smaller than 100 nucleotides.

6. The method according to any one of the preceding claims, characterized in that at least one of the primers can be immobilized and the probe is detectably marked.

7. The method according to any one of the preceding claims, characterized in that at least one of the primers is detectable and the probe is marked immobilizable or immobilized.

8. The method according to any one of the preceding claims, characterized in that the probe is marked by both a fluorescence quencher and a fluorescent dye.

9. The method according to any one of the preceding claims, characterized in that one of the primers is marked by a first energy transfer component and the probe by a second, different energy transfer component.

10. The method according to any one of the preceding claims, characterized in that the amplificate is detected by physical and / or spectroscopic methods.

11. The method according to any one of the preceding claims, characterized in that at least one of the primers is not specific for the nucleic acid to be detected.

12. The method according to claim 11, characterized in that two of the primers are not specific for the nucleic acid to be detected.

13. The method according to any one of claims 11 and 12, characterized in that the probe is not specific for the nucleic acid to be detected.

14. The method according to any one of the preceding claims, characterized in that nucleotides complementary to A, G, C and T are used in the amplification.

15. A method for the detection of a nucleic acid comprising the steps

- Production of a large number of amplificates of a section of these

Nucleic acid with the aid of two primers, one of which can bind to a binding sequence A of the nucleic acid and of which the other can bind to a binding sequence C which is complementary to a sequence C which does not overlap with A and is located in the 3 ′ direction of A , and detection of the amplificates by mass spectroscopy.

16. A method for the specific detection of a nucleic acid comprising the steps

Production of a large number of amplificates of a section of this nucleic acid using at least two primers,

Contacting the amplificates with a probe which can bind to the amplificate, and

Detection of the formation of a hybrid from the amplificate and the probe,

characterized in that at least one of the primers is not specific for the nucleic acid to be detected.

17. The method according to claim 16, characterized in that two of the primers are not specific for the nucleic acid to be detected.

18. The method according to any one of claims 16 and 17, characterized in that the probe is not specific for the nucleic acid to be detected.

19. The method according to any one of claims 16 to 18, characterized in that nucleotides complementary to A, G, C and T are used in the amplification.

20. A process for the simultaneous production of amplificates of parts of nucleic acids, in which primers are used which allow amplification of these parts with the different sequences, characterized in that the primers are selected so that the amplificates formed no longer by their length differ by 20% and are no longer than 100 nucleotides.

21. The method according to claim 20, characterized in that amplicons of nucleic acids of HIV, HBV and HCV are simultaneously produced.

22. A method for the detection of HCV, characterized in that primers and probes are used, the sequences of which are sequences from sequences of consecutive bases of the HGBV sequences from FIG. 7 or sequences complementary thereto

Sequences with more than 80% identity are taken from these sequences.